The Claim
Exendin-4 undergoes tissue-specific metabolic degradation in rat kidney and liver homogenates, with kidney tissue exhibiting multiple early cleavage events and liver tissue showing a dominant initial endoproteolytic cleavage at the Ser11-Lys12 bond, followed by exoproteolytic trimming.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In rats, the body breaks down a substance called exendin-4 differently in the kidneys and liver — the kidneys chop it up in several places early on, while the liver makes one main cut first and then trims the ends.
See the scientific wording
The degradation of exendin-4 in rat kidney and liver homogenates follows distinct metabolic pathways, with kidney tissue showing multiple early cleavage events and liver tissue exhibiting a dominant initial endoproteolytic cut at Ser11-Lys12, followed by exoproteolytic trimming.
What the research says
1 studyStudy: In Vitro Metabolic Stability of Exendin-4: Pharmacokinetics and Identification of Cleavage Products
The study shows that in rat tissues, exendin-4 breaks down differently in the kidney and liver, just like the claim says — quickly in many places in the kidney, and starting at one main spot in the liver.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.